Relevant bibliographies by topics / Mood stabilizer / Books
To see the other types of publications on this topic, follow the link: Mood stabilizer.

Books on the topic 'Mood stabilizer'

Author: Grafiati
Published: 4 June 2021
Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 38 books for your research on the topic 'Mood stabilizer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Corson, Timothy William. Mood stabilizer effects on expression of signal transducer genes implicated in bipolar disorder. Ottawa: National Library of Canada, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Stahl, S. M. Mood stabilizers. Cambridge: Cambridge University Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

M, Stahl S., ed. Antipsychotics and mood stabilizers: Stahl's essential psychopharmacology, 3rd edition. Cambridge: Cambridge University Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

de Leon, Jose, ed. A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities. Boston, MA: Springer US, 2012. http://dx.doi.org/10.1007/978-1-4614-2012-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

De Aquino, João Paulo, and Robert Beech. Mood Stabilizer Monotherapy versus Adjunctive Antidepressant for Bipolar Depression. Edited by Ish P. Bhalla, Rajesh R. Tampi, Vinod H. Srihari, and Michael E. Hochman. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190625085.003.0004.

Full text
Abstract:
This chapter provides a summary of a landmark study on bipolar disorder, which aims to address the following question: In patients with bipolar disorder receiving mood-stabilizing agents, does adjunctive antidepressant therapy reduce the symptoms of bipolar depression without increasing the risk for mania? Starting with that question, the chapter describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints and results, in addition criticisms and limitations. Subsequently, other relevant studies are briefly reviewed and their clinical implications are discussed. Finally, a relevant clinical exemplifies the application of the current evidence behind the clinical question addressed by the study.
APA, Harvard, Vancouver, ISO, and other styles
6

Kwan, Melodie. Effect of the mood stabilizer valproate on intracellular calcium homeostatis in bipolar I disorder. 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Goldberg, Pablo H., Prerna Martin, Carolina Biernacki, and Moira A. Rynn. Treatments for Pediatric Bipolar Disorder. Oxford University Press, 2015. http://dx.doi.org/10.1093/med:psych/9780199342211.003.0009.

Full text
Abstract:
The past two decades have seen significant advances in the development of evidence-based treatments for pediatric bipolar disorder. Practice guidelines recommend pharmacotherapy with mood stabilizers or second-generation antipsychotics (SGAs) as the first-line treatment. Lithium, risperidone, aripiprazole, quetiapine, and olanzapine are approved by the U.S. Food & Drug Administration for treating bipolar disorder in children and adolescents. The pharmacological literature suggests that SGAs are faster and more effective than mood stabilizers in treating acute manic or mixed episodes, but they have significant side effects and require careful monitoring. While mild to moderate bipolar disorder can be treated with monotherapy, combination pharmacotherapy with an SGA and a mood stabilizer is recommended for youth with severe bipolar disorder. A growing body of literature also suggests the efficacy of psychosocial interventions, with family psychoeducation and skills building as adjunct treatments to pharmacotherapy. More type 1 studies of pharmacotherapy and psychosocial treatments are needed.
APA, Harvard, Vancouver, ISO, and other styles
8

Cavanna, Andrea E. Phenytoin. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198791577.003.0010.

Full text
Abstract:
Phenytoin is a first-generation antiepileptic drug characterized by a good range of antiepileptic indications, with an acceptable interaction profile in polytherapy. The reasons for the decreased use of phenytoin in patients with epilepsy include its narrow therapeutic index and potential for long-term toxicity, as well as the development of other antiepileptic drugs throughout the second half of the twentieth century. Phenytoin has a good behavioural tolerability profile and a restricted range of psychiatric uses. Despite occasional reports of adverse behavioural effects (especially at higher doses), there is some weak evidence for its potential usefulness as mood stabilizer and in the pharmacological management of impulsive aggression.
APA, Harvard, Vancouver, ISO, and other styles
9

Tacchi, Mary Jane, and Jan Scott. 5. The evolution of treatments. Oxford University Press, 2017. http://dx.doi.org/10.1093/actrade/9780199558650.003.0005.

Full text
Abstract:
For many centuries, the only intervention for melancholia involved admission into an asylum, initially to keep individuals away from society and then, from the 18th century, to provide therapeutic care. ‘The evolution of treatments’ discusses the crude treatments that were first introduced for inpatients such as sedation (barbiturates and insulin coma therapy) and physical treatments (electroconvulsive therapy and psychosurgery). Next, it discusses the development of the medications that are used today for inpatients and outpatients, such as antidepressants and the mood stabilizer lithium. Finally, it looks at the evolution of psychotherapies from early Freudian models through to mindfulness and the potential barriers to providing psychological interventions in the real world.
APA, Harvard, Vancouver, ISO, and other styles
10

Hazell, Philip. The treatment of bipolar disorder in children and adolescents. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198748625.003.0021.

Full text
Abstract:
The presentation of bipolar disorder in young people can be different from that of adults; therefore, the approach to treatment differs slightly. Treatment is described for early intervention, acute mania, bipolar depression, relapse prevention, and refractory bipolar disorder. A strong therapeutic alliance with the patient and engagement and involvement of the patient’s family is critical to successful intervention. The evidence informing treatment is limited, but there is emerging research focused on the management of acute mania favouring monotherapy with a second-generation antipsychotic (SGA) over a mood stabilizer. Preliminary data favour a combination of an SGA and antidepressant over monotherapy with an SGA for the treatment of bipolar depression. Guidelines endorse electroconvulsive therapy for refractory mania and bipolar depression but there is no clinical trial evidence to support this practice. The development of algorithms to guide the management of all phases of bipolar disorder is a work in progress.
APA, Harvard, Vancouver, ISO, and other styles
11

The use of generic mood stabilizers. Memphis, TN: Physicians Postgraduate Press, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

institute, neuroscience education. Mood Stabilizers and Atypical Antipsychotics (4 of 4). nei press, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Association, American Psychiatric. Pocket Guide to Medications: Anxiolytics, Mood Stabilizers, and ADHD. American Psychiatric Association Publishing, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Stahl, Stephen M. Essential Psychopharmacology of Antipsychotics and Mood Stabilizers (Essential Psychopharmacology Series). Cambridge University Press, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Gupta, Neha. Treatment of Psychiatric Disorders. Edited by Isis Burgos-Chapman. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190265557.003.0006.

Full text
Abstract:
In this chapter, essential aspects of the treatment of psychiatric disorders are reviewed including pharmacokinetics, pharmacodynamics, drug interactions, psychogenomics and the use of antidepressants, mood stabilizers, antianxiety agents, antipsychotics, psychostimulants, hypnotics and sedatives, ECT and psychotherapy
APA, Harvard, Vancouver, ISO, and other styles
16

Singh, Harvinder, Miyun Kang, Sarah de Asis, Rajiv Radhakrishnan, Rajesh R. Tampi, Esha Sharma, Geetha Manikkara, Silpa Balachandran, Mahitha Kolli, and Suneela Cherlopalle. Treatment of Psychiatric Disorders. Edited by Rajiv Radhakrishnan and Lily Arora. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190265557.003.0028.

Full text
Abstract:
In this chapter the treatment of psychiatric disorders are reviewed including antidepressants, mood stabilizers, antianxiety agents, antipsychotics, psychostimulants, hypnotics, sedatives, electroconvulsive therapy, vagal nerve stimulation, psychotherapy, repetitive transcranial nerve stimulation (rTMS), vagal nerve stimulation and self-help groups
APA, Harvard, Vancouver, ISO, and other styles
17

Essential Psychopharmacology: the Prescriber's Guide: Antipsychotics and Mood Stabilizers (Essential Psychopharmacology Series). Cambridge University Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

Fabbri, Chiara, and Alessandro Serretti. The treatment of bipolar disorder in the era of personalized medicine: myth or promise? Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198748625.003.0031.

Full text
Abstract:
Bipolar disorder (BD) is a chronic disease associated with high personal and socio-economic burden. Genetics accounts for 20–95% of variability in central nervous system drug disposition and pharmacodynamics, thus genetic markers are considered a promising way to develop tailored treatments and improve the prognosis of the disease. Among mood stabilizers, lithium response was the most investigated phenotype and the most replicated genes are involved in synaptic plasticity (BDNF), serotonergic (SLC6A4) and dopaminergic (DRD1) neurotransmission, and second messenger cascades (GSK3B). Relevant pharmacogenetic findings regarding other mood stabilizers are hyperammonaemia (CPS1 gene) and hepatic dysfunction (POLG gene) induced by valproate and immune-mediated cutaneous hypersensitivity reactions (HLA-B*1502) induced by lamotrigine or carbamazepine. Polymorphisms in cytochrome (CYP) P450 genes are expected to provide useful information particularly in case of polypharmacy. Despite few pharmacogenetic tests are currently recommended, the development of pharmacogenetics in other fields of medicine provides an encouraging perspective.
APA, Harvard, Vancouver, ISO, and other styles
19

A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
20

Fountoulakis, Konstantinos N., and Dimos Dimellis. The treatment of rapid cycling bipolar disorder. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198748625.003.0006.

Full text
Abstract:
Rapid cycling may complicate the course of a significant proportion of patients with bipolar disorder (BD). It is defined in DSM-5 by the occurrence of at least four distinct mood episodes in 12 months. Rapid cycling BD has been consistently associated with worse outcomes compared with non-rapid cycling BD. Thus, rapid cycling BD may require specific treatment strategies. Antidepressants, antipsychotics, and mood stabilizers/anticonvulsants have been studied either as monotherapy or in combination treatments. Concerning the treatment of acute mood episodes, the best available data exist for atypical antipsychotics. On the other hand, maintenance or relapse-prevention treatment, and newer-generation antipsychotics and anticonvulsants seem to be efficacious for rapid cycling BD. Lithium may also be efficacious. Treatment with antidepressants should be avoided in this subpopulation of patients. Overall, few randomized controlled trials have been conducted, and many have been underpowered. Therefore, a significant gap remains in evidence-based treatment of rapid cycling BD.
APA, Harvard, Vancouver, ISO, and other styles
21

Burns, Tom, and Mike Firn. The role of medication. Edited by Tom Burns and Mike Firn. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198754237.003.0007.

Full text
Abstract:
This chapter focuses mainly on the importance of maintenance antipsychotic medication and mood stabilizers. It examines procedures to support persistence with these drugs and maintain engagement. The techniques for initiating and monitoring clozapine therapy in the community for patients with resistant schizophrenia are outlined. The practical processes for ensuring and conducting regular structured reviews of long-term medication, both to assess progress and to identify side effects, are described in detail. In addition, the judicious use of antidepressants and benzodiazepines is outlined.
APA, Harvard, Vancouver, ISO, and other styles
22

Friedel, Robert O., and Stephen M. Stahl. The Fundamentals of Brain Neurotransmission. Edited by Christian Schmahl, K. Luan Phan, Robert O. Friedel, and Larry J. Siever. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199362318.003.0002.

Full text
Abstract:
This chapter outlines the fundamental principles underlying neuroscience, particularly as it relates to neurotransmission and neuropharmacology. It then reviews and synthesizes of the role of different neurochemical and neurotransmitter systems that underlie brain function and synaptic transmission, including GABA, glutamate, serotonin, dopamine, norepinephrine, acetylcholine, and histamine. In addition, it describes various psychoactive medications are used in the treatment of personality disorders, such as mood stabilizers and antipsychotics. Moreover, it describes how these agents target these systems by describing their different mechanisms of action. It provides a primer to better understand the pathophysiology and pharmacological treatment of personality disorders discussed in the book.
APA, Harvard, Vancouver, ISO, and other styles
23

Cavanna, Andrea E. Valproate. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198791577.003.0014.

Full text
Abstract:
Valproate is a first-generation antiepileptic drug characterized by a wide range of antiepileptic indications, with an acceptable interaction profile in polytherapy. Valproate has a good behavioural tolerability profile, despite the existence of occasional reports of depression, irritability, and other behavioural symptoms in patients with encephalopathy. Valproate is also characterized by a wide range of psychiatric uses. Most importantly, valproate is an effective mood stabilizser, with a licensed indication for the treatment of acute mania in patients with bipolar affective disorder. Although it has no formal indication, it is also considered as a first-line agent for maintenance treatment in bipolar affective disorder.
APA, Harvard, Vancouver, ISO, and other styles
24

Series, Hugh. The Treatment of Depression. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780198801900.003.0010.

Full text
Abstract:
This chapter considers some of the physical options for the treatment of the affective disorders, depression, and mania. It first provides an historical overview of physical treatments for depression, including drugs such as opium, morphine, and diamorphine, chloral, and barbiturates, as well as electroconvulsive therapy (ECT). It then examines whether antidepressants work and how they are used before describing the biological basis of depression. It also looks at different classes of antidepressants, including monoamine oxidase inhibitors (MAOIs), reuptake inhibitors, and mood stabilizers. Finally, it evaluates non-pharmacological physical treatments ranging from ECT to transcranial magnetic stimulation (TMS), psychosurgery and deep brain stimulation, and novel therapies.
APA, Harvard, Vancouver, ISO, and other styles
25

Soule, Michael, and Hilary S. Connery. Co-occurring Substance Use Disorders. Edited by Hunter L. McQuistion. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190610999.003.0020.

Full text
Abstract:
Substance use disorders are frequently comorbid with mood, anxiety, and psychotic disorders, and they commonly present in tandem in both primary care and psychiatric settings. Unfortunately, in the past, individuals with co-occurring substance use and mental health disorders would receive treatment in community mental health clinics only after their substance use disorder was “stabilized.” There has been increasing recognition that integrated treatment is necessary for these individuals to fully succeed and achieve recovery. This chapter uses a common presentation to illustrate up-to-date screening and treatment recommendations. Motivational interviewing, contingency management, cognitive–behavioral therapy, and medication-assisted treatment are explored. A discussion of the continuum of community-based services and systems challenges follows.
APA, Harvard, Vancouver, ISO, and other styles
26

Ellison, Justin C., Jason B. Rosenstock, and Michael J. Marcsisin. Somatic Treatments for Psychotic Disorders. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199331505.003.0006.

Full text
Abstract:
A variety of somatic therapies can be used to treat individuals suffering from psychosis. Most commonly, providers will prescribe antipsychotics, which generally block dopamine receptors and are particularly useful at reducing positive symptoms. Second-generation antipsychotics have fewer movement side effects than older agents do, but they are more expensive and have more metabolic side effects. Long-acting injectable (LAI) antipsychotics can be useful for improving outcomes, especially in non-adherent patients, and clozapine is the gold standard for treatment-refractory psychosis. Other agents may be useful for adjunct therapy, or in early psychosis, such as antidepressants, mood stabilizers, and benzodiazepines. In this chapter, we will also review other somatic therapies such as electroconvulsive therapy (ECT) and other neuromodulation approaches.
APA, Harvard, Vancouver, ISO, and other styles
27

Burns, Tom, and Mike Firn. Bipolar affective disorder. Edited by Tom Burns and Mike Firn. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198754237.003.0016.

Full text
Abstract:
This chapter deals with the other major psychotic illness, bipolar affective disorder. Bipolar disorder poses a difficult question for outreach workers, as patients are often well recovered between episodes—so should persisting outreach be provided? We report very good results in severe bipolar disorder where continuity of care has paid off. The chapter also deals with theories of causation and classification. The section on treatment identifies the importance of early admission in hypomania, the use of mood stabilizers, and the value of identifying and agreeing on relapse signatures. It also confirms the value of working hard to strengthen the therapeutic relationship and of psychosocial interventions such as psycho-education. Long-term work with these patients brings home just how persistent and disabling the depressive phases can be.
APA, Harvard, Vancouver, ISO, and other styles
28

Perez-Rodriguez, M. Mercedes, and Larry J. Siever. Psychopharmacological Treatment of Personality Disorders. Oxford University Press, 2015. http://dx.doi.org/10.1093/med:psych/9780199342211.003.0028.

Full text
Abstract:
Despite the lack of approval by the U.S. Food & Drug Administration, drugs are used widely to treat personality disorders, particularly borderline personality disorder, based on their effects known from clinical trials in other psychiatric disorders (off-label use). The role of medications in personality disorders is limited to moderate effects on some but not all of the symptom domains. There are no medications available that improve the global severity of any personality disorder as a whole. In borderline personality disorder, evidence is strongest for second-generation antipsychotics and mood stabilizers, while dietary supplements like omega-3 fatty acids hold some promise. However, medications have limited effectiveness and are still viewed as adjunctive to other forms of treatment, particularly psychotherapy.
APA, Harvard, Vancouver, ISO, and other styles
29

Stewart, Jessica Ann, L. Mark Russakoff, and Jonathan W. Stewart. Pharmacotherapy, ECT, and TMS. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199326075.003.0016.

Full text
Abstract:
Physicians’ attention to patients’ concerns and attitudes about taking medication will engender adherence, as will close monitoring of potentially disconcerting side effects. The primary indication for antipsychotic medications is the treatment of psychotic disorders and mania, even in the absence of psychosis. The more troublesome side effects of antipsychotic medications include increased appetite and weight gain; extrapyramidal side effects, tardive dyskinesia, and neuroleptic malignant syndrome. Antidepressants are effective for treating depressive illness, including major depression, persistent depressive disorder (dysthymia) and premenstrual dysphoric disorder. They are also often used effectively in the treatment of anxiety disorders, obsessive-compulsive disorder, bulimia nervosa, and somatic symptom disorders. Selective serotonin reuptake inhibitors (SSRIs) are generally well tolerated. Other important categories of medications include mood stabilizers and anxiolytics.
APA, Harvard, Vancouver, ISO, and other styles
30

Perova, Tatiana. Differential modulation of intracellular calcium responses in B lymphoblasts by mood stabilizers: Relevance to the molecular therapeutics of bipolar disorder. 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

Fozdar, Manish A., and Jacob C. Holzer. Psychopharmacological Agents, Side Effects, and Black Box Warnings. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199374656.003.0015.

Full text
Abstract:
From a medical-legal viewpoint, psychopharmacological management in the elderly population requires a multifaceted, comprehensive approach, involving a detailed clinical diagnostic assessment, an awareness of a patient’s current medical status, risk factors, and an understanding of the risks and benefits of various treatment options. Several risk management strategies can be employed as part of the treatment process, which are reviewed in this chapter. Special attention is needed in the pharmacological management of the elderly population with respect to efficacy and risk as well as polypharmacy. It is important that clinicians have a broad understanding of the different medication classes, including antidepressants, antipsychotics, mood stabilizers, cognitive-enhancing medications, benzodiazepines, sedative-hypnotics, and stimulants; specific agents; indications; kinetics; and side effects in both the clinical management of elderly patients and in medical-legal consultation.
APA, Harvard, Vancouver, ISO, and other styles
32

Barnes, Thomas R. E. Pharmacological management of treatment-resistant schizophrenia: alternatives to clozapine. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198828761.003.0009.

Full text
Abstract:
Other than for clozapine, there are no pharmacological interventions with robust evidence of a positive benefit–risk balance for the treatment-resistant schizophrenia. For patients with treatment-resistant schizophrenia, there is usually little to be gained, in comparison to switching the antipsychotic to clozapine, from alternatives such as a further switch to a non-clozapine antipsychotic medication, the prescription of high-dose or combined antipsychotic medications, or the augmentation of continuing antipsychotic medication with other medications, such as antidepressants, mood stabilizers, or benzodiazepines. However, where these are tried, each initiation of high-dose or combined antipsychotic medication or an augmentation strategy should be treated as an individual trial and appropriately monitored and reviewed, with discontinuation in case of inefficacy or benefit that is outweighed by safety or tolerability concerns.
APA, Harvard, Vancouver, ISO, and other styles
33

Vasudev, Akshya. Manic syndromes in old age. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199644957.003.0044.

Full text
Abstract:
Manic syndromes in the elderly are different from those seen in the younger bipolar population. They are a heterogenous group but can probably be divided into two main groups based on age of onset of the illness: late onset bipolar disorder (LOB) and early onset bipolar disorder (EOB). This chapter elaborates on differences in these two groups based on epidemiological data findings, clinical presentation, aetiopathogenesis and management. Latest concepts with regards to the vascular mania hypothesis, neuroimaging findings, cognitive impairment in bipolar disorder are also dealt with. A critical review of pharmacological management options is also provided with reference to recently published data on mood stabilisers, antipsychotic and antidepressant usage for this age group.
APA, Harvard, Vancouver, ISO, and other styles
34

Popovic, Dina, and Eduard Vieta. Evidence-based maintenance treatment of bipolar disorder. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198748625.003.0008.

Full text
Abstract:
Due to the episodic and chronic nature of bipolar disorder, maintenance therapy represents a critical part of treatment. However, there is a paucity of studies comparing effectiveness of available long-term treatments. In this chapter, the efficacy and safety of pharmacological treatments for maintenance treatment of bipolar disorder, as deriving from the results of randomized controlled trials, will be critically reviewed. These include second-generation antipsychotics aripiprazole, olanzapine, quetiapine, risperidone long-acting injection, ziprasidone, paliperidone, and mood stabilizers lamotrigine, lithium, valproate, carbamazepine, and oxcarbazepine. In general, if a patient has responded satisfactorily to a certain drug during the acute phase, the same treatment should be maintained during maintenance treatment. This was confirmed in two randomized controlled trials. This chapter summarizes the characteristics of the placebo-controlled randomized controlled trials for all the antipsychotics used for maintenance treatment of bipolar disorder.
APA, Harvard, Vancouver, ISO, and other styles
35

Perugi, Giulio, Giulia Vannucchi, and Lorenzo Mazzarini. The treatment of cyclothymia. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198748625.003.0010.

Full text
Abstract:
The treatment of cyclothymia is problematic due to its rather complex clinical picture (early onset, lack of clear-cut episodes, high co-morbidity), a challenging patient–doctor relationship and a high sensitivity to medications. This chapter summarizes available evidence on pharmacological treatment, psychoeducation, and psychotherapy for cyclothymic patients. The management of cyclothymia should rely on integrated strategies. The psychopharmacological treatment has to follow the principle of ‘go slow and stay low’. Mood stabilizers should be the first option and antidepressants and antipsychotics should be used cautiously and for short periods of time to manage depressive, anxious, or hypomanic symptoms. Psychoeducation should be started from the beginning and is aimed to promote a better knowledge of the disorder and its effects on daily life as well as adherence to medications. The inclusion of individual psychotherapeutic treatments (eg, cognitive behavioural treatment) should also be considered.
APA, Harvard, Vancouver, ISO, and other styles
36

Barthel, Andreas, and Michael Bauer. Psychotropic drugs and metabolic risk. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198789284.003.0011.

Full text
Abstract:
Increased appetite and weight gain represent a significant problem related with particular antipsychotic drugs, antidepressants, mood stabilizers, and—to a lesser extent—anxiolytic drugs. Psychotropic drug-induced weight gain may contribute to obesity-related metabolic changes and pathological conditions such as dyslipidaemia, type-2-diabetes and hypertension—summarized as the metabolic syndrome—with an increased risk for cardiovascular morbidity and mortality. Interestingly, psychotropic drugs are also used for the treatment of diabetes-related complications. For example, antidepressants are effective for the treatment of neuropathic pain in patients with diabetic neuropathy. Therefore, it is essential to thoroughly balance potential benefits and risks in an individual patient to ensure drug safety and optimize the clinical outcome. In addition to diet and exercise, selection of psychotropic drugs and dose adjustment based on regular clinical follow-up visits is the key for the prevention and management of psychotropic drug induced weight gain in clinical practice.
APA, Harvard, Vancouver, ISO, and other styles
37

Kass, Erica, Jonathan E. Posner, and Laurence L. Greenhill. Pharmacological Treatments for Attention-Deficit/Hyperactivity Disorder and Disruptive Behavior Disorders. Oxford University Press, 2015. http://dx.doi.org/10.1093/med:psych/9780199342211.003.0004.

Full text
Abstract:
More than 225 placebo-controlled type 1 investigations demonstrate that psychostimulants are highly effective in reducing core symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adults. In contrast, there are limited type I studies demonstrating that psychopharmacological management with U.S. Food & Drug Administration-approved agents for ADHD (stimulants and nonstimulants), atypical antipsychotics, and mood stabilizers decrease the defiant and aggressive behavior characteristic of disruptive behavior disorders. Stimulant treatment evidence has been supplemented by two large multisite randomized controlled trials. Randomized controlled trials from the past 15 years continue to report several key adverse events associated with stimulants but have not supported rarer and more serious problems. Although psychostimulants have been shown to retain their efficacy for as long as 14 months, their long-term academic and social benefits are not as robust. Nonstimulant agents for which there is more limited evidence of efficacy include atomoxetine, alpha-agonists, modafinil, and bupropion.
APA, Harvard, Vancouver, ISO, and other styles
38

Ansari, Arash, and David Osser. Psychopharmacology. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780197537046.001.0001.

Full text
Abstract:
Psychopharmacology: A Concise Overview, 3rd Edition discusses and reviews currently available psychiatric medications and their evidence-supported use in current clinical practice. It discusses the therapeutic uses of antidepressants, anti-anxiety medications, antipsychotics, mood stabilizers, stimulants, and other medications for attention-deficit/hyperactivity disorder (ADHD), as well as medicines for substance use disorders. It reviews the medications’ mechanisms of action, therapeutic effects, potential drug–drug interactions and short- and long-term adverse effects and risks. It includes sections on complementary and alternative pharmacotherapies as well as on emerging therapies. Every chapter includes an in-depth discussion of the clinical use of the reviewed classes of medications as they are used for the alleviation of their target psychiatric disorders, such as depression, anxiety disorders, schizophrenia, bipolar disorder, ADHD, and opioid, alcohol, and tobacco use disorders. Treatment challenges and controversies are reviewed. In addition, each chapter discusses the use of these medications in other psychiatric and medical conditions as well. Each chapter also discusses the use of these medications in women of childbearing age, especially in light of pregnancy and breastfeeding considerations. Finally, each chapter includes a table that provides each reviewed medicine’s generic and brand names, usual adult doses, pertinent clinical comments, black box warnings, and Food and Drug Administration indications. This book provides a concise and accessible overview that would be helpful to medical students, psychiatric residents, psychiatrists, primary care physicians, clinical nurse specialists, and nonmedical mental health practitioners.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Mood stabilizer' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography